Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 9/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 9/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 9/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 9/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.37 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562367 | 0.82 | MET (0.61) | METABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL10212439 | 0.82 | MET (0.44) | METABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL10212435 | 0.80 | ABCC9 (0.42) | METABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL9906873 | 0.77 | MET (0.65) | METROCK1KDM4E | |
| SCHEMBL10212438 | 0.76 | MET (0.43) | METABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL9906858 | 0.68 | MET (0.48) | METROCK1 | |
| SCHEMBL10212419 | 0.68 | MET (0.45) | METABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL10212464 | 0.67 | MET (0.44) | METABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL10212427 | 0.67 | MET (0.44) | METABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL1583361 | 0.66 | MET (0.80) | METROCK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | MET, RET, ERBB2 | MET 1/4885PLK4 599/4885ABCC9 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.